Research Article
Warfarin Accelerates Aortic Calcification by Upregulating Senescence-Associated Secretory Phenotype Maker Expression
Table 2
Baseline characteristics according to absence and presence of AC in AF patients with warfarin treatment.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Data are presented as . Male, smoking, hypertension, clopidogrel, statin, and CHD are presented as (%). SBP, DBP, HR, ALP, hsCRP, and warfarin duration are presented as median (interquartile range). values are from independent-sample -test, Mann-Whitney test, chi-squared test, and Fisher’s exact test for appropriate data between group AC and group no AC (). AF: atrial fibrillation; ALP: alkaline phosphatase; BMI: body mass index; DBP: diastolic blood pressure; GLU: glucose; HCRP: high-sensitivity C-reactive protein; HDL-c: high-density lipoprotein cholesterol; HR: heart rate; INR: international normalized ratio; LA: left atrium; LDL-c: low-density lipoprotein cholesterol; LVEF: left ventricular ejection fraction; LVPWT: left ventricular posterior wall thickness; SBP: systolic blood pressure; TC: total cholesterol; TG: triglyceride. |